Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
KeCheng Fine Chemicals

US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures

Patents

CNIPA Launches Pilot for Priority Patent Review for Macau Applicants in Mainland China

CancerFRA: MVR0

Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide

AbbVieBeiGene

AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa

Show More